Company / Revenue per Share
Charles River Laboratories Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$81.59
FY2025
5-year range
$52.67 / $81.59
FY2021-FY2025
Trend
+3.4%
vs FY2024
Sector context
#27 of 154
Health Care
What the data says
Charles River Laboratories's revenue per share of $81.59 is higher than 82% of companies in the Health Care sector (FY2025). Revenue per Share has increased for 6 consecutive years, from $38.53 in FY2019 to $81.59 in FY2025.
Based on SEC 10-K filings.
81.59 in FY2025 with a 5-year CAGR of +12.0%. Top quartile in the Health Care sector.
Improved from $69.49 to $81.59 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +12.1%
- 5-Year CAGR
- +12.0%
- 10-Year CAGR
- -
Sector benchmark
-34.2% below sector average
Key checks
Key Insights
- Charles River Laboratories's revenue per share has grown for 6 consecutive years.
- In FY2025, revenue per share increased 3.4% year-over-year.
- Ranks #27 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $81.59 | +3.4% |
| FY2024 | $78.89 | +13.5% |
| FY2023 | $69.49 | +20.0% |
| FY2022 | $57.92 | +10.0% |
| FY2021 | $52.67 | +13.7% |
| FY2020 | $46.31 | +20.2% |
| FY2019 | $38.53 | -19.4% |
| FY2018 | $47.81 | +407.9% |
| FY2017 | $9.41 | -73.9% |
| FY2016 | $36.01 | +46.2% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026